TY - JOUR
T1 - Feasibility of photodynamic diagnosis for challenging TUR-Bt cases including muscle invasive bladder cancer, BCG failure or 2nd-TUR
AU - Takai, Tomoaki
AU - Inamoto, Teruo
AU - Komura, Kazumasa
AU - Yoshikawa, Yuki
AU - Uchimoto, Taizo
AU - Saito, Kenkichi
AU - Tanda, Naoki
AU - Kouno, Junko
AU - Minami, Koichiro
AU - Uehara, Hirofumi
AU - Takahara, Kiyoshi
AU - Hirano, Hajime
AU - Nomi, Hayahito
AU - Kiyama, Satoshi
AU - Azuma, Haruhito
PY - 2015
Y1 - 2015
N2 - Background: Despite widely adopted standard methods for follow-up including cystoscopy plus cytology, recurrence rates of non muscle-invasive bladder cancer (NMIBC) have not improved over the past decades, still ranging from 60% through 70%. Hence, widely acceptable surveillance strategies with excellent sensitivity are needed. Early recurrence has led to the development of a novel cystoscopy technique utilizing photodynamic diagnosis (PDD). Although, no studies have evaluated the efficacy of PDD for patients of MIBC, BCG failure or 2nd-transurethelial resection (TUR). Materials and Methods: The present study was performed from October 2012 through May 2013. IRB approved 25 patients initially underwent a cystoscopy examination of white light and blue light followed by the resection of tumors identified. Resections were performed from bladder mucosa areas considered suspicious at PDD, along with PDD negative normal bladder mucosa area resected by random biopsy. Specimens were divided into two groups, PDD positive and negative. Primary endpoints were sensitivity and specificity. Results: A total of 147 specimens extracted from 25 patients were included in the analysis. Some 45 out of 92 PDD-positive specimens were confirmed to have bladder cancer, and 51 out of PDD-negative 55 specimens were confirmed to be cancer negative. The sensitivity of PDD was 91.8% (45/49) and specificity was 52.0% (51/98). The sensitivity:specificity was 89.5% (17/19): 47.6% (30/63) in 12 2nd-TUR patients, 90.5% (19/21): 61.1% (11/18) in seven MIBC patients, and 95.0% (19/20): 48.5% (16/33) in eight failed BCG cases. Conclusions: PDD-TURBT has high sensitivity to diagnose BC even for 2nd-TUR, MIBC or BCG failure cases.
AB - Background: Despite widely adopted standard methods for follow-up including cystoscopy plus cytology, recurrence rates of non muscle-invasive bladder cancer (NMIBC) have not improved over the past decades, still ranging from 60% through 70%. Hence, widely acceptable surveillance strategies with excellent sensitivity are needed. Early recurrence has led to the development of a novel cystoscopy technique utilizing photodynamic diagnosis (PDD). Although, no studies have evaluated the efficacy of PDD for patients of MIBC, BCG failure or 2nd-transurethelial resection (TUR). Materials and Methods: The present study was performed from October 2012 through May 2013. IRB approved 25 patients initially underwent a cystoscopy examination of white light and blue light followed by the resection of tumors identified. Resections were performed from bladder mucosa areas considered suspicious at PDD, along with PDD negative normal bladder mucosa area resected by random biopsy. Specimens were divided into two groups, PDD positive and negative. Primary endpoints were sensitivity and specificity. Results: A total of 147 specimens extracted from 25 patients were included in the analysis. Some 45 out of 92 PDD-positive specimens were confirmed to have bladder cancer, and 51 out of PDD-negative 55 specimens were confirmed to be cancer negative. The sensitivity of PDD was 91.8% (45/49) and specificity was 52.0% (51/98). The sensitivity:specificity was 89.5% (17/19): 47.6% (30/63) in 12 2nd-TUR patients, 90.5% (19/21): 61.1% (11/18) in seven MIBC patients, and 95.0% (19/20): 48.5% (16/33) in eight failed BCG cases. Conclusions: PDD-TURBT has high sensitivity to diagnose BC even for 2nd-TUR, MIBC or BCG failure cases.
UR - http://www.scopus.com/inward/record.url?scp=84929191059&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929191059&partnerID=8YFLogxK
U2 - 10.7314/APJCP.2015.16.6.2297
DO - 10.7314/APJCP.2015.16.6.2297
M3 - Article
C2 - 25824753
AN - SCOPUS:84929191059
SN - 1513-7368
VL - 16
SP - 2297
EP - 2301
JO - Asian Pacific Journal of Cancer Prevention
JF - Asian Pacific Journal of Cancer Prevention
IS - 6
ER -